NJEDA Technology Business Tax Certificate Transfer Program (NOL)

NJEDA Technology Business Tax Certificate Transfer Program (NOL)

Supports New Jersey investors with tax certificate transfer structures that help recycle capital into technology business growth.

Eligibility · United States · US-NJ

The New Jersey Technology Business Tax Certificate Transfer Program, administered by the New Jersey Economic Development Authority (NJEDA), allows qualifying technology and life sciences businesses to convert accumulated New Jersey net operating losses (NOLs) and unused research and development tax credits into immediate cash by selling those tax attributes to profitable corporate buyers. The program effectively creates a secondary market for tax losses: participating companies receive up to 90 cents on the dollar for NOL certificates, generating cash proceeds that can range from $40,000 to $20 million or more depending on the size of the NOL pool and available program capacity. This mechanism is particularly valuable to pre-revenue or loss-generating startups in biotechnology, medical technology, clean technology, and information technology that hold substantial deferred tax assets they cannot use against current-year New Jersey tax liability.

Eligibility is restricted to for-profit companies operating in New Jersey's technology and life sciences sectors with fewer than 225 employees and gross revenues below $10 million in the prior tax year. The company must have a net operating loss for the tax year in question under New Jersey law and must hold qualifying R&D-related losses or credits generated from in-state activity. The program is administered by NJEDA in coordination with the New Jersey Division of Taxation; companies apply through NJEDA's portal and, upon approval, receive certificates that are then sold to unrelated profitable corporations. Annual program capacity is finite, meaning demand can exceed supply and companies may not be able to transfer the full value of their NOL in a single year.

For early-stage companies in New Jersey's innovation economy, the NOL transfer program functions as a de facto non-dilutive cash infusion mechanism, allowing them to monetize a tax attribute that would otherwise sit dormant for years. Strategic applicants typically stack this program with federal SBIR/STTR awards and New Jersey's other innovation incentives to maximize non-dilutive capital. The award ceiling of $20 million reflects the statutory cap on transfers per company; the practical median for growth-stage biotech and tech companies is significantly lower, in the $1–3 million range per year.